CN1679796A - Anti-cancer compound preparation of giant knotweed, Tengli root and thinleaf adina root and its making method and use - Google Patents
Anti-cancer compound preparation of giant knotweed, Tengli root and thinleaf adina root and its making method and use Download PDFInfo
- Publication number
- CN1679796A CN1679796A CN 200510032666 CN200510032666A CN1679796A CN 1679796 A CN1679796 A CN 1679796A CN 200510032666 CN200510032666 CN 200510032666 CN 200510032666 A CN200510032666 A CN 200510032666A CN 1679796 A CN1679796 A CN 1679796A
- Authority
- CN
- China
- Prior art keywords
- radix
- preparation
- polygoni cuspidati
- actinidiae chinensis
- gei japonici
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An antineoplastic Chinese medicine in the form of tablet or capsule for treating and preventing intestinal cancer, stomach cancer, etc is prepared from the giant knotweed rhizome, thin leaf adina root, etc through pulverizing, proportional mixing, extracting in hot water, flocculating deposition, filtering or centrifugal separating, regulating pH value, adsorbing eluting, vacuum concentrating, drying, pulverizing and shaping.
Description
Technical field
The present invention relates to Chinese medicine formula, particularly a kind of anti-tumor compound Chinese herbal and crude drugs preparations and its production and application.
Background technology
Mainly comprise polygoni cuspidati,radix, Radix Actinidiae Chinensis and Radix Gei japonici in three prescriptions of compound recipe, derive from the experience prescription, its proportioning be the equivalent proportioning (Yu Rencun, tumor prescription choosing commonly used, traditional Chinese medical science oncology, 1997:21).When treatment digestive tract tumor, point out it to have remarkable antitumor effect (Bao Suzhen, Sun Zaidian etc., three soup of Chinese medicine compound are in conjunction with chemotherapeutic treatment middle and advanced stage colorectal cancer 120 examples, Liaoning Journal of Traditional Chinese Medicine, 1992 (7): 33～34), but effective ingredient wherein is also indeterminate, is not further studied.
Rhizoma Polygoni Cuspidati is the root of Polygonaceae herbaceos perennial Rhizoma Polygoni Cuspidati (Polygonum cuspidatum Sieb.et Zucc.), has heat-clearing and toxic substances removing, expelling wind and removing dampness, the effect of promoting blood circulation to restore menstrual flow, the hydroxyl anthraquinone analog compound mainly contains emodin, physcione, chrysophanol, resvertrol glycoside, resvertrol and multiple polysaccharide etc.Polygoni cuspidati,radix is better to murine sarcoma 180 and human cervical cancer cell inhibiting rate, and 50% decoct has inhibitory action to staphylococcus aureus, bacillus pyocyaneus, Bacillus typhi and shigella flexneri etc.; Effective ingredient in the Rhizoma Polygoni Cuspidati is an anthraquinone analog compound, its pharmacological research gets more (Zhang Xiyun, the chemical constituent of Rhizoma Polygoni Cuspidati, pharmacological action and extraction separation, the Tianjin pharmacy, 1999,11 (3): 13), but the separation method of its effective site is studied lessly, and the someone adopts percolation, soak, reflux, Soxhlet extract and ultrasonic extracting method to the extraction ratio of Rhizoma Polygoni Cuspidati anthraquinone study (once, Yuan's pendant, the research of Rhizoma Polygoni Cuspidati anthraquinone optimization of extraction and isolation, China's Pharmaceutical, 2003,12 (9): 45～48), finally better with 70% ethanol extracting, extraction ratio is up to 1.58%; Resveratrol is the another anticancer active constituent in the Rhizoma Polygoni Cuspidati of discovered in recent years, but the content in Rhizoma Polygoni Cuspidati is lower, only is 0.1%.Publication number be reported employing organic solvent extraction, extraction in the Chinese invention patent of CN1277954A, concentrated, silica gel column chromatography, crystallization, recrystallization obtain the higher degree resveratrol; Publication number is that the Chinese invention patent of CN1341587A discloses and utilizes the direct abstraction technique of ethyl acetate; Publication number is that the Chinese invention patent of CN1513822A discloses microwave-assisted extraction technique, and publication number is that the Chinese invention patent of CN1513823A discloses supercritical CO
2Abstraction technique, publication number are that the Chinese invention patent of CN1546503A discloses with polyamide chromatography isolation technics.The all not mentioned macroporous resin extraction method simple and easy to do, with low cost of above technology is not directly used in compound medicine with the effective site of extracting yet.
Radix Actinidiae Chinensis is the fall leaves root of big liana Fructus actinidiae chinensis (Actinidia chinensis Planch.) of Actinidiaceae, having detoxifcation and invigorating blood circulation, and the effect of clearing away heat-damp and promoting diuresis contains vitamin C, saccharide, pigment and aminoacid.Someone found it have antitumaous effect (Chen Dexuan, Pan Liqun, the anti-tumor botanical Radix Actinidiae Chinensis, Chinese crude drug, 2004,27 (2): 86～87), its ethanol extraction intraperitoneal administration to the test S180 inhibitor be 30～40%.Someone studies its composition, the extract of finding ethyl acetate reaches 54% and 60% (Zou friend and mentor respectively to leukaemia and colon cancer poorly differentiated adenocarcinoma cell inhibiting rate, Tan Guishan, Xie Zhaoxia, Radix Actinidiae Chinensis suppresses the experimentation of tumor cell, Chinese medicine Leader, Hunan, 1999,5 (4): 37～38), but its effective site and method of separating component are not done further research, also do not have relevant patent.
Radix Gei japonici is the root of Rubiaceae defoliation bush plant Fructus Adinae (Adina rubella (Sieb.etZucc.) Hance), has heat-clearing and toxic substances removing, the effect of the silt pain relieving of loosing.Root alcohol extractum every day is with 5g/kg continuous irrigation stomach or lumbar injection 6d, to mouse leukemia L
615Inhibitory action is arranged, and suppression ratio is 21.4%, to cervical cancer cell and white mice sarcoma AK, and the rat sarcoma all have inhibitory action (Yu Rencun, tumor use Chinese herbal medicine, traditional Chinese medical science oncology, 1997:72), this prompting it the broad-spectrum anti-tumor effect is arranged.At present research rests on the superficial understanding to medical material to Radix Gei japonici, does not therefrom find main anticancer active constituent, therefore discloses its active component and the mechanism of action, has directive significance for its research and development as antitumor drug.Contain catechin compounds in the flowers and fruits preface of Fructus Adinae, other has ursolic acid, oleanolic acid, cupreol, Fructus Adinae first element and alkaloid etc., but the effective ingredient of Radix Gei japonici report is less, have only how to go straight up to etc. and (how to go straight up to etc., the Fructus Adinae The Chemical Constituents, Chinese herbal medicine, 1996,26 (6): 285～288) once reported employing silica gel column chromatography isolating several new Quinovic acid glycoside compounds in Radix Gei japonici, but failed to carry out anti-tumor activity research.Quinovic acid glucosides also is found in other anticancer plants, in ledger bark, found this kind chemical compound as far back as Raffauf RF in 1978 etc., has anti-tumor activity, in other plant, also find (Raffauf RF later on, etal.Antitumor Plants.V Constituents of Cinchona pubescens, Lloydia, 1978,41 (5): 432～434), show that it also might be a main anti-tumor active substance in the Radix Gei japonici.But its effective site and method of separating component are not done further research.
The macroporous resin separation method and the preparation technique at polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici and prescription effective ingredient or position are not seen relevant report.
Summary of the invention
The objective of the invention is provides a kind of anti-tumor compound polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici preparation in order to solve defective and the deficiency that above-mentioned prior art exists.
Another object of the present invention provides a kind of preparing such formulations.
A further object of the present invention provides the application of a kind of above-mentioned preparation in the medicine of tumor diseases such as preparation treatment or prevention colorectal cancer, gastric cancer.
The object of the invention is achieved through the following technical solutions: this anti-tumor compound polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici preparation are to be made by following raw material by weight: polygoni cuspidati,radix 2～5; Radix Actinidiae Chinensis 1～3; Radix Gei japonici 1～3.
The preparation method that above-mentioned each component is made preparation of the present invention may further comprise the steps:
(1) polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici Chinese crude drug or its ground product are mixed, use the hot water lixiviate, 80～100 ℃ of water temperatures, 1～2 hour extraction time, medicinal residues are removed in filtration or centrifugalize, keep extracting solution; The hot water lixiviate repeats to extract 2～3 times, merge extractive liquid;
(2) add flocculating agent in extracting solution, staticly settle, precipitation is gone in filtration or centrifugalize;
(3) regulate pH value, staticly settle, precipitation is gone in filtration or centrifugalize, obtains supernatant;
(4) with supernatant after macroporous resin adsorption, use the organic solvent eluting;
(5) with after eluent concentrating under reduced pressure, the drying, be ground into fine powder;
(6) with behind the gained fine powder interpolation auxiliary type agent, make tablet or capsule.
In the hot water lixiviate in the described step (1), liquid medicine is than being respectively that liquid medicine is than 1: 8～12 for the first time, and liquid medicine is than 1: 4～6 for the second time, and liquid medicine is than 1: 4～6 for the third time, and wherein liquid medicine is than being mass percent; Described extracting solution can be through concentrating or without concentrating.
Flocculant addition in the described step (2) can preferably be 0.1～1% of a medical material amount by weight percentage.Flocculating agent can be in chitin, ZTC flocculating agent (Tianjin became clarification technique company limited product in positive day) or the gelatin etc. any.
Extracting liquid pH value in the described step (3) is adjusted to 2～5, and regulating the pH value agents useful for same is acid reagents such as hydrochloric acid or acetic acid.
Macroporous resin in the described step (4) is the macroporous resin that contains various nonpolar or low poles; The used organic solvent of eluting can be organic solvents such as ethanol water, aqueous acetone solution.
The described drying process of described step (5) can be methods such as vacuum drying, spray drying or lyophilization.
With anti-tumor compound polygoni cuspidati,radix, Radix Actinidiae Chinensis, the Radix Gei japonici preparation of the present invention's preparation, the medicament that can be used to prepare treatment or prevent tumors such as colorectal cancer, gastric cancer, rectal cancer; Described medicament can be the dosage form that comprises on any pharmaceutics.
The relative prior art of the present invention has following advantage and effect: (1) adopts 80～100 ℃ of lixiviates 2～3 times, each 1～2 hour, can improve the rate of transform of effective ingredient in the medical material as far as possible; (2) adopt the flocculating agent precipitation, avoided ethanol precipitation to reclaim the steps that increase more because of precipitating the loss and the ethanol that not exclusively cause; (3) adopt the acid adjustment method, remove acid non-soluble substance, improve the macroporous resin absorption effect; (4) adopt macroporous resin refining to active component in the extracting solution, the effective site of purification Chinese medicine polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici (active constituent content reaches more than 80%) is convenient to suitability for industrialized production effectively; (5) effective site with polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici is mixed and made into preparation by a certain percentage, can effectively improve bioavailability, improves drug effect; (6) fill up the shortage of existing polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici effective site separation and Extraction and preparation, developed a kind of novel anti-tumor effective component or preparation of active ingredient.
The specific embodiment
The present invention is described in further detail below in conjunction with embodiment, but embodiments of the present invention are not limited thereto.
Embodiment 1
Polygoni cuspidati,radix 2Kg, Radix Actinidiae Chinensis 1Kg, Radix Gei japonici 1Kg are ground into coarse powder, add 100 ℃ of boiling water 40L, timing lixiviate 90 minutes, during keep heating, keep slight boiling condition.Filter, filtering residue adds 100 ℃ of boiling water 20L again, timing lixiviate 60 minutes, during keep heating, keep slight boiling condition.Filter, abandon filtering residue, merge twice filtrate, filtrate is concentrated into ratio of specific heat through normal pressure and weighs 1.05, adds flocculating agent chitin 4g, stirs centrifugal (3000 rev/mins of back, 10 minutes), keep supernatant, transfer pH to 2, leave standstill with 10%HCl, the centrifugal precipitation (the same condition) of going, supernatant is through macroporous resin HPD100, with the medical material effective ingredient that 70% ethanol water eluting is adsorbed, eluent decompression recycling ethanol, vacuum is greater than 0.04Mpa, residue vacuum drying, vacuum be greater than 0.01Mpa, 3 hours drying times.Make dry product 105g altogether, anthraquinone analog compound content 89% in this dry product.
Embodiment 2
Polygoni cuspidati,radix 5Kg, Radix Actinidiae Chinensis 1Kg, Radix Gei japonici 1Kg are ground into coarse powder, add 100 ℃ of boiling water 84L, timing lixiviate 120 minutes, during keep heating, keep slight boiling condition.Centrifugal (3000 rev/mins, 10 minutes), filtering residue adds 100 ℃ of boiling water 41L again, timing lixiviate 120 minutes, during keep heating, keep slight boiling condition.Centrifugal (3000 rev/mins, 15 minutes), abandon filtering residue, merge twice centrifugal liquid, add flocculating agent gelatin 70g, stir after-filtration, filtrate is transferred pH to 5 with 5%HCl, leave standstill, cross the elimination precipitation, supernatant is through macroporous resin HPD300, the medical material effective ingredient that is adsorbed with 80% aqueous acetone solution eluting, eluent decompression recycling ethanol, vacuum be greater than 0.04Mpa, the residue lyophilization, temperature-50 ℃, make dry product 95g 24 hours drying times altogether, anthraquinone analog compound content 96% in this dry product.
Embodiment 3
Polygoni cuspidati,radix 3Kg, Radix Actinidiae Chinensis 2Kg, Radix Gei japonici 1Kg through being ground into coarse powder, add 100 ℃ of boiling water 48L, timing lixiviate 60 minutes, during keep heating, keep slight boiling condition.Filter, filtering residue adds 100 ℃ of boiling water 24L again, timing lixiviate 60 minutes, during keep heating, keep slight boiling condition.Filter, filtering residue adds 100 ℃ of boiling water 24L again, timing lixiviate 60 minutes, during keep heating, keep slight boiling condition.Filter, abandon filtering residue, merge three times filtrate, filtrate weighs 1.05 (vacuum is greater than 0.04Mpa) through being evaporated to ratio of specific heat, adds the ZTC flocculating agent 30g that Tianjin became the clarification technique company limited to produce in positive day, stirs centrifugal (3000 rev/mins of back, 10 minutes), keep supernatant, transfer pH to 3, leave standstill with 20% acetic acid 1, the centrifugal precipitation (the same condition) of going, supernatant is through macroporous resin HPD600, with the medical material effective ingredient that 60% ethanol water eluting is adsorbed, eluent decompression recycling ethanol, vacuum is greater than 0.04Mpa, the residue spray drying, 180 ℃ of inlet temperature, 90 ℃ of outlet temperatures.Make dry product 112g altogether.Anthraquinone analog compound content 92% in this dry product.
Embodiment 4
Polygoni cuspidati,radix 2Kg, Radix Actinidiae Chinensis 3Kg, Radix Gei japonici 3Kg are ground into coarse powder, add 80 ℃ of water 80L, timing lixiviate 90 minutes, during keep heating, keep 80 ℃.Filter, filtering residue adds 80 ℃ of water 40L again, timing lixiviate 60 minutes, during keep heating, keep 80 ℃.Filter, abandon filtering residue, merge twice filtrate, filtrate is concentrated into ratio of specific heat through normal pressure and weighs 1.05, adds flocculating agent chitin 10g, stirs centrifugal (3000 rev/mins of back, 10 minutes), keep supernatant, transfer pH to 2, leave standstill with 10%HCl, the centrifugal precipitation (the same condition) of going, supernatant is through macroporous resin D101, with the medical material effective ingredient that 80% ethanol water eluting is adsorbed, eluent decompression recycling ethanol, vacuum is greater than 0.04Mpa, residue vacuum drying, vacuum be greater than 0.01Mpa, 4 hours drying times.Make dry product 135g altogether.Anthraquinone analog compound content 86% in this dry product.
Embodiment 5
Polygoni cuspidati,radix 3Kg, Radix Actinidiae Chinensis 3Kg, Radix Gei japonici 2Kg are ground into coarse powder, add 90 ℃ of water 96L, timing lixiviate 120 minutes, during keep heating, keep 90 ℃.Centrifugal (3000 rev/mins, 10 minutes), filtering residue adds 90 ℃ of water 41L again, timing lixiviate 120 minutes, during keep heating, keep 90 ℃.Centrifugal (3000 rev/mins, 15 minutes) abandon filtering residue, merge twice centrifugal liquid, add flocculating agent gelatin 40g, stir after-filtration, filtrate is transferred pH to 5 with 5%HCl, leaves standstill, and crosses the elimination precipitation, supernatant is through macroporous resin HPD300, with the medical material effective ingredient that 70% aqueous acetone solution eluting is adsorbed, eluent decompression recycling ethanol, vacuum is greater than 0.04Mpa, the residue lyophilization, temperature-50 ℃, 24 hours drying times.Make dry product 103g altogether.Anthraquinone analog compound content 98% in this dry product.
Embodiment 6
Polygoni cuspidati,radix 3Kg, Radix Actinidiae Chinensis 1Kg, Radix Gei japonici 2Kg through being ground into coarse powder, add 90 ℃ of water 54L, timing lixiviate 60 minutes, during keep heating, keep 90 ℃.Filter, filtering residue adds 90 ℃ of water 27L again, timing lixiviate 60 minutes, during keep heating, keep 90 ℃.Filter, filtering residue adds 90 ℃ of water 24L again, timing lixiviate 60 minutes, during keep heating, keep 90 ℃.Filter, abandon filtering residue, merge three times filtrate, filtrate weighs 1.05 (vacuum is greater than 0.04Mpa) through being evaporated to ratio of specific heat, add ZTC flocculating agent 50g, stir back centrifugal (3000 rev/mins, 10 minutes), keep supernatant, transfer pH to 3 with 20% acetic acid 1, leave standstill, the centrifugal precipitation (the same condition) of going, supernatant is through macroporous resin HPD600, the medical material effective ingredient that is adsorbed with 70% ethanol water eluting, eluent decompression recycling ethanol, vacuum be greater than 0.04Mpa, the residue spray drying, 180 ℃ of inlet temperature, 90 ℃ of outlet temperatures make dry product 98g altogether, anthraquinone analog compound content 95% in this dry product.
Embodiment 7
Take by weighing the effective site dry product 1Kg that embodiment 2 makes, add medical starch, Icing Sugar and 7: 2: 1 mixture 2Kg of dextrin mass ratio, mix homogeneously, wet granulation, water is regulated, make loose particles, be convenient to the tabletting state, cross 20 mesh sieves, dry, add the 15g magnesium stearate, tabletting promptly gets the tablet of three effective sites of compound recipe.
Embodiment 8
Take by weighing the effective site dry product 1Kg that embodiment 1 makes, add medicinal microcrystalline Cellulose 2Kg, mix homogeneously, wet granulation, water is regulated, and makes loose particles and crosses 20 mesh sieves, dries, and dry back filled capsules promptly gets three effective site capsules of compound recipe.
Embodiment 9
Take by weighing the effective site dry product 1Kg that embodiment 3 makes, add 6Kg PEG6000 (polyethylene glycol 6000), be heated to mix homogeneously after 60 ℃ of fusings, place in the drop pill machine, use liquid paraffin refrigeration, drop pill.Cooling promptly gets the drop pill of three effective sites of compound recipe.
Embodiment 10
Take by weighing the effective site dry product 1Kg that embodiment 4 makes, add 2Kg mannitol, after the aquesterilisa dissolving, cross 0.3 μ m microporous filter membrane, cannedly go in the ampere bottle ,-50 ℃ of lyophilizations 24 hours promptly get the freeze-dried powder of three effective sites of compound recipe.
Embodiment 11
With tumor cell (2 * 10
6/ ml), put into 96 aseptic hole culture plates, every hole adds tumor cell suspension 50 μ l, add the RPMI-1640 50 μ l that contain 15% calf serum, add embodiment 1 solution of extract 10 μ l, every group 3 hole, add the normal saline vibration mixing of equivalent in the hole, put into 5% CO then
2Incubator (37 ℃) is cultivated 24h, adds tetrazolium salts (MTT) phosphate buffer, and every hole 10 μ l (every ml contains MTT5mg) continue to cultivate 4h, add dimethylsulfone 100ml then, cessation reaction is with enzyme glue immune detection instrument, respectively at wavelength 570nm, the 630nm place measures optical density OD value, result of calculation.
Computing formula:
In gastric cancer RF cell strain and the experiment of rectal cancer LS174T cell strain tumor cell culture, find, three effective sites of compound recipe are significantly higher than three water extracts of compound recipe (concentrated solution that directly adds 2 hours rear filtrates of 10 times of boiling water extraction of weight ratio) to the suppression ratio of two kinds of tumors, and its tumor killing effect improves with dosage escalation.The results are shown in Table one.
Three effective sites of table one compound recipe are to the inhibition experiment of gastric cancer and rectum cancer cell
| Handle | Concentration (mg/ml) | To gastric cancer suppression ratio % (x ± SD) | To rectal cancer suppression ratio % (x ± SD) |
| Three effective sites of three effective part compounds of three water extracts of compound recipe (2: 1: 1) compound recipe | ???5 ? ????1 ? ???2 ? | ?26.4±2.4 ? ?53.6±5.3 ? ?81.7±7.4 ? | ?33.3±3.1 ? ?57.2±4.8 ? ?86.5±6.7 ? |
| Three effective sites of compound recipe | 5 | ????97.7±5.5 | ??95.1±5.9 |
Embodiment 12
Method: get mice S180 tumor piece, dilution and adjustment cell number to 1 * 10 after the homogenate
7/ ml, it is subcutaneous to inject the right axil of mice with 0.2ml, random packet administration behind the 24h, cyclophosphamide (CTX) group intraperitoneal administration, normal saline (matched group), three effective part extract groups of the compound recipe of three decocting liquid groups (concentrated solution that directly adds 2 hours rear filtrates of 10 times of boiling water extraction of weight ratio) and embodiment 1 are irritated stomach, and the execution mice of weighing in the 11st day is got the tumor piece, claim that tumor is heavy and survey the tumor volume, calculate tumour inhibiting rate.
The result: three decocting liquid are 36.8% to the S180 tumour inhibiting rate, and the tumour inhibiting rate of three effective sites of isodose compound recipe is 65.5%, and there were significant differences with matched group, and not remarkable with the difference of CTX, points out it to have good antitumor action.The results are shown in Table two.
Three effective sites of table two compound recipe are to the inhibition zoopery of S180 sarcoma
| Grouping | Dosage (g/Kg) | Tumor heavy (g) (x ± SD) | Tumor volume (cm 3) ??( x±SD) | Tumour inhibiting rate (%) |
| Three active components of control group CTX group three effective part compounds of decocting liquid group (2: 1: 1) compound | ? ?25 ?15 ?? ?10 ?? ?15 | ?3.42±0.46 ?1.12±0.26 ?2.16±0.38 ? ?1.45±0.32 ? ?1.18±0.29 | ??2.85±0.73 ??0.81±0.37 ??1.94±0.66 ? ??1.22±0.35 ? ??0.85±0.43 ? | ? ??67.2 ??36.8 ? ??57.6 ? ??65.5 |
Claims (9)
1, a kind of Polygoni Cuspidati Composite root, Radix Actinidiae Chinensis, Radix Gei japonici preparation is characterized in that: made by following raw material by weight: polygoni cuspidati,radix 2～5; Radix Actinidiae Chinensis 1～3; Radix Gei japonici 1～3.
2, a kind of method for preparing the described Polygoni Cuspidati Composite root of claim 1, Radix Actinidiae Chinensis, Radix Gei japonici preparation is characterized in that may further comprise the steps:
(1) polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici Chinese crude drug or its ground product are mixed, use the hot water lixiviate, 80～100 ℃ of water temperatures, 1～2 hour extraction time, medicinal residues are removed in filtration or centrifugalize, keep extracting solution; The hot water lixiviate repeats to extract 2～3 times, merge extractive liquid;
(2) add flocculating agent in extracting solution, staticly settle, precipitation is gone in filtration or centrifugalize;
(3) regulate pH value, staticly settle, precipitation is gone in filtration or centrifugalize, obtains supernatant;
(4) with supernatant after macroporous resin adsorption, use the organic solvent eluting;
(5) with after eluent concentrating under reduced pressure, the drying, be ground into fine powder;
(6) with behind the gained fine powder interpolation auxiliary type agent, make tablet or capsule.
3, the preparation method of Polygoni Cuspidati Composite root according to claim 2, Radix Actinidiae Chinensis, Radix Gei japonici preparation, it is characterized in that: in the hot water lixiviate in the described step (1), liquid medicine than be respectively for the first time liquid medicine than 1: 8～12, liquid medicine is than 1: 4～6 for the second time, liquid medicine is than 1: 4～6 for the third time, and wherein liquid medicine is than being mass percent;
4, the preparation method of Polygoni Cuspidati Composite root according to claim 2, Radix Actinidiae Chinensis, Radix Gei japonici preparation is characterized in that: the flocculant addition in the described step (2) is 0.1～1% of medical material amount by weight percentage.
5, the preparation method of Polygoni Cuspidati Composite root according to claim 2, Radix Actinidiae Chinensis, Radix Gei japonici preparation is characterized in that: the extracting liquid pH value in the described step (3) is adjusted to 2～5, and regulating the pH value agents useful for same is hydrochloric acid or acetic acid.
6, the preparation method of Polygoni Cuspidati Composite root according to claim 2, Radix Actinidiae Chinensis, Radix Gei japonici preparation is characterized in that: the macroporous resin in the described step (4) is the macroporous resin that contains various nonpolar or low poles; The used organic solvent of eluting is ethanol water, aqueous acetone solution.
7, the preparation method of Polygoni Cuspidati Composite root according to claim 2, Radix Actinidiae Chinensis, Radix Gei japonici preparation is characterized in that: the drying in the described step (5) is vacuum drying, spray drying or lyophilization.
8, the application of Polygoni Cuspidati Composite root according to claim 1, Radix Actinidiae Chinensis, Radix Gei japonici preparation is characterized in that: the medicament that is used to prepare treatment or prevents tumors such as colorectal cancer, gastric cancer, rectal cancer.
9, the application of Polygoni Cuspidati Composite root according to claim 8, Radix Actinidiae Chinensis, Radix Gei japonici preparation is characterized in that: described medicament can be the dosage form that comprises on any pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100326666A CN100546602C (en) | 2005-01-04 | 2005-01-04 | Anti-tumor compound polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici preparation and its production and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100326666A CN100546602C (en) | 2005-01-04 | 2005-01-04 | Anti-tumor compound polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici preparation and its production and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679796A true CN1679796A (en) | 2005-10-12 |
| CN100546602C CN100546602C (en) | 2009-10-07 |
Family
ID=35066802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100326666A Expired - Fee Related CN100546602C (en) | 2005-01-04 | 2005-01-04 | Anti-tumor compound polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici preparation and its production and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100546602C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335252A (en) * | 2011-09-28 | 2012-02-01 | 华南理工大学 | Oral targeting preparation of compound three-root extract for resisting colorectal cancer and preparation method thereof |
| CN103301218A (en) * | 2012-12-29 | 2013-09-18 | 浙江省中医院 | Chinese herbal preparation for treating colon cancer and preventing cancer metastasis and preparation method thereof |
| CN111450155A (en) * | 2020-05-19 | 2020-07-28 | 浙江中医药大学 | Body resistance strengthening and detoxifying formula and method for coarsely crushing root of Chinese waxberry |
-
2005
- 2005-01-04 CN CNB2005100326666A patent/CN100546602C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335252A (en) * | 2011-09-28 | 2012-02-01 | 华南理工大学 | Oral targeting preparation of compound three-root extract for resisting colorectal cancer and preparation method thereof |
| CN102335252B (en) * | 2011-09-28 | 2013-02-13 | 华南理工大学 | Oral targeting preparation of compound three-root extract for resisting colorectal cancer and preparation method thereof |
| CN103301218A (en) * | 2012-12-29 | 2013-09-18 | 浙江省中医院 | Chinese herbal preparation for treating colon cancer and preventing cancer metastasis and preparation method thereof |
| CN111450155A (en) * | 2020-05-19 | 2020-07-28 | 浙江中医药大学 | Body resistance strengthening and detoxifying formula and method for coarsely crushing root of Chinese waxberry |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100546602C (en) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1723981A (en) | Novel use of extractive of Momordica grosvenori as adjuvant drug for preparing medicine | |
| KR101579219B1 (en) | Composition containing complex extracts for preventing, improving or treating colitis | |
| CN100500196C (en) | Method for preparing paris polyphylla total saponin | |
| CN1116894C (en) | Medicine for treating cardiovascular disease and preparation process thereof | |
| WO2008007063A2 (en) | Anti-obesity product and it's method of preparation | |
| CN102342945B (en) | Application of Cortex Ilicis Rotundae saponin compound in preparing anti-inflammatory and analgetic medicament | |
| WO2002067962A1 (en) | The method for preparating an anemone raddeana extract and the pharmaceutical composition containing the same as well as use thereof | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| CN102772497B (en) | Alcohol extraction effective part of medicinal material of Relinqing granules and preparation method thereof | |
| CN100546602C (en) | Anti-tumor compound polygoni cuspidati,radix, Radix Actinidiae Chinensis, Radix Gei japonici preparation and its production and application | |
| CN1486712A (en) | Extractive of Chinese medicinal material rabdosia as antitumor medicine and its prepn process | |
| CN107260777B (en) | Refined fiveleaf akebia fruit total saponin with anti-tumor activity and application thereof | |
| CN100546601C (en) | Radix Gei japonici antineoplastic extract and its production and use | |
| CN1016141B (en) | Preparation method of new type sanguisorba pharmaceutical | |
| CN100546590C (en) | Anti-cancer Tengli root extract and its production and use | |
| CN101919919A (en) | Fukean dispersible tablet and preparation method thereof | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN1695649A (en) | Soft capsule of extractive from active ingredient of jingangteng, and preparation method | |
| CN100333746C (en) | Method for preparing Chinese medicine preparation for treating chronic conjestive heart-failure | |
| KR100549662B1 (en) | Composition comprising the extract or fraction isolated from Russian Mumie for activation of Immunity | |
| CN1476839A (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN112915066B (en) | Glabrous sarcandra herb formula granules and preparation method thereof | |
| CN1739548A (en) | The Omithogalum caudatum polysaccharide medicine of treatment hepatocarcinoma | |
| CN113350459A (en) | A method for preparing Chinese medicinal oral liquid for treating lung cancer and quality control method thereof | |
| CN117414384A (en) | Compound Chinese herbal medicine preparation for resisting colorectal cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091007 Termination date: 20120104 |